



Zosano Pharma
Investor Relations Department
34790 Ardentech Ct.
Fremont, CA 94555
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ZSAN

Last Trade:	17.44
Trade Time:	4:00 PM ET Mar 16, 2018
Change:	1.94 (+12.516%)
Day Range	17.01 - 21.45
52-Week Range	3.61 - 41.60
Volume	4,160,648


Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Zosano Pharma is an emerging CNS company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy, but altering their delivery profile using the Company's proprietary transdermal delivery system. The Company's goal is to make transdermal drug delivery a standard of care for delivering drugs requiring fast onset of action.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Mar 16, 2018

[Zosano Reaches Enrollment Milestone in M207-ADAM Long-term Safety Study](#)

Mar 12, 2018

[Zosano Pharma Reports Fourth Quarter and Fiscal Year 2017 Financial Results and Operational Update](#)

Mar 2, 2018

[Zosano Pharma Announces Issuance of New U.S. Patent Covering M207 as an Acute Treatment for Migraine](#)

Jan 25, 2018

[Zosano Announces Results of Special Meeting of Stockholders and 1-for-20 Reverse Stock Split](#)

Jan 3, 2018

[Zosano Pharma Announces Notice of Allowance for a U.S. Patent Application Covering M207 as an Acute Treatment for Migraine](#)

Financials [\[View all \]](#)

Mar 12, 2018

[Annual Report \(10-K\)](#)

Dec 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 10, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)